Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Replication of the EMPA-REG OUTCOME Diabetes Trial in Healthcare Claims

Next Previous
Trial Profile

Replication of the EMPA-REG OUTCOME Diabetes Trial in Healthcare Claims

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EMPAREG

Most Recent Events

  • 25 Jul 2023 Status changed from active, no longer recruiting to completed.
  • 29 Jun 2021 Results of post hoc, pooled analysis from EMPA-REG OUTCOME assessing the total burden of mortality and events leading to or prolonging hospitalization in patients with T2D and ASCVD, with a clinically relevant number of events prevented and a low number needed to treat, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
  • 17 May 2021 Results of a pooled analysis from six clinical trials: EMPAREG, DAPA-HF, EMPEROR-REDUCTION, VERTIS-CV, SOLOIST-WHF and SCORED presented at the 70th Annual Scientific Session of the American College of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top